Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

Authors :: Rossini M
Viapiana O
Orsolini G
Fracassi E
Idolazzi L
Gatti D
Adami S
Govoni M
Source :: Reumatismo [Reumatismo] 2015 Mar 31; Vol. 66 (4), pp. 285-303. Date of Electronic Publication: 2015 Mar 31.
Publication Year :: 2015
Abstract: Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

Subjects :: Arthritis, Rheumatoid drug therapy
Humans
Randomized Controlled Trials as Topic
Treatment Outcome
Antibodies, Monoclonal therapeutic use
Antirheumatic Agents therapeutic use
Arthritis, Psoriatic drug therapy
Spondylitis, Ankylosing drug therapy

Full Text Access

Tools